Shanghai Haohai Biological Technology Valuation

Q: What is the Fair Price of 6826 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6826 (HK$30.6) is trading below our estimate of [[fair value]] (HK$132.55)

Is 6826 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6826 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6826 (HK$30.6) is trading below our estimate of fair value (HK$132.55)

Significantly Below Fair Value: 6826 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6826?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 6826. This is calculated by dividing 6826's market cap by their current preferred multiple.
What is 6826's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥13.67b

6826 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.3x
Enterprise Value/EBITDA	20.8x
PEG Ratio	0.8x

Price to Earnings Ratio vs Peers

How does 6826's PE Ratio compare to its peers?

The above table shows the PE ratio for 6826 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.4x
1530 3SBio	7.5x	14.6%	HK$13.6b
2696 Shanghai Henlius Biotech	15.6x	11.5%	HK$11.8b
6955 Shandong Boan Biotechnology	72.6x	n/a	HK$4.9b
1061 Essex Bio-Technology	5.9x	n/a	HK$1.5b
6826 Shanghai Haohai Biological Technology	15x	18.6%	HK$15.0b

Price-To-Earnings vs Peers: 6826 is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (25.4x).

Price to Earnings Ratio vs Industry

How does 6826's PE Ratio compare vs other companies in the Asian Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	41.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	41.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 6826 is good value based on its Price-To-Earnings Ratio (15x) compared to the Asian Biotechs industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 6826's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6826 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15x
Fair PE Ratio	13.1x

Price-To-Earnings vs Fair Ratio: 6826 is expensive based on its Price-To-Earnings Ratio (15x) compared to the estimated Fair Price-To-Earnings Ratio (13.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.